



cells



an Open Access Journal by MDPI

## Chimeric Antigen Receptor T-Cell Therapy

Guest Editor:

### Prof. Dr. Michael Schmitt

1. Department of Internal  
Medicine V, University Hospital  
Heidelberg, 69120 Heidelberg,  
Germany

2. German Cancer Research  
Center (DKFZ), National Center  
for Tumor Diseases (NCT),  
German Cancer Consortium  
(DKTK), 69120 Heidelberg,  
Germany

Deadline for manuscript  
submissions:

**closed (30 April 2020)**

### Message from the Guest Editor

Dear Colleagues,

CAR T cell therapy with two commercial products recently came into clinical practice both in the US and Europe. Hematologists and oncologist are getting more and more familiar with the potential of CAR T cell therapy, its effectiveness, and side effects.

Clinical practice taught us that therapy is safe when physicians and nurses are well-prepared and instructed in the classification of side effects as well as in therapeutic algorithms. The clinical effectiveness of CAR T cells depends on tumor size, number and functionality of cells, and the therapy line in which CAR T cell therapy is employed.

Every day, we are discovering new aspects of CAR T cell therapy and that we need new tools and algorithms to make CAR T cell therapy more effective. Additionally, the entire process is translational: Clinicians have to learn from researchers and vice versa. That sparks new excitement and enthusiasm.

The aim of this Special Issue is to address preclinical, translational, and clinical aspects of current CAR T cell therapy for researchers and clinicians working in the field.

Prof. Dr. Michael Schmitt

*Guest Editor*



[mdpi.com/si/30967](https://mdpi.com/si/30967)

# Special Issue



*cells*



an Open Access Journal by MDPI

## Editors-in-Chief

### **Prof. Dr. Alexander E. Kalyuzhny**

Neuroscience, UMN Twin Cities,  
6-145 Jackson Hall, 321 Church St  
SE, Minneapolis, MN 55455, USA

### **Prof. Dr. Cord Brakebusch**

Biotech Research & Innovation  
Centre, The University of  
Copenhagen, Copenhagen,  
Denmark

## Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (*General Biochemistry, Genetics and Molecular Biology*)

## Contact Us

*Cells* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cells](http://mdpi.com/journal/cells)  
[cells@mdpi.com](mailto:cells@mdpi.com)  
[X@Cells\\_MDPI](https://twitter.com/Cells_MDPI)